Primary Record
CGI-1746
Note: Only for scientific research or as raw materials for production.
- In stock
- 5,714 g
- Purity
- 99.7 %
- CAS
- 910232-84-7
Compound Identifiers & Properties
- CAS
- 910232-84-7
- PubChem CID
- 24857323
- SMILES
- CC1=C(C=CC=C1NC(=O)C2=CC=C(C=C2)C(C)(C)C)C3=CN(C(=O)C(=N3)NC4=CC=C(C=C4)C(=O)N5CCOCC5)C
- Canonical SMILES
- Cc1c(NC(=O)c2ccc(C(C)(C)C)cc2)cccc1-c1cn(C)c(=O)c(Nc2ccc(C(=O)N3CCOCC3)cc2)n1
Names & Synonyms
- CGI-1746
- 910232-84-7
- CGI1746
- RefChem:918300
- D0H3JH
- MFCD18782602
- 4-(tert-Butyl)-N-(2-methyl-3-(4-methyl-6-((4-(morpholine-4-carbonyl)phenyl)amino)-5-oxo-4,5-dihydropyrazin-2-yl)phenyl)benzamide
- CGI 1746
- SCHEMBL769731
- GCI1746
- C34H37N5O4
- GTPL8066
- orb1305433
- CHEMBL1230541
- SCHEMBL29359902
- BDBM36516
- CGI-560
- CGI-676
- DTXSID70647724
- EX-A614
- SYN1164
- JIFCFQDXHMUPGP-UHFFFAOYSA-N
- GLXC-90238
- HMS3652B20
- AOB87149
- BCP05160
- CGI-1316
- CGI-2233
- CGI-2815
- CGI-3130
- KS-00001CV0
- CGI-1746?
- s7051
- ZINC58631343
- AKOS024462679
- BCP9000510
- CCG-270125
- CGI1746, 2
- CS-0252
- EBC-220069
- SB19189
- NCGC00345857-01
- NCGC00345857-06
- NCGC00345857-10
- AC-35289
- AK162846
- AS-16300
- BC600469
- CID 24857323
- DA-34985
- HY-11999
- 4-tert-butyl-N-[2-methyl-3-[4-methyl-6-[4-(morpholine-4-carbonyl)anilino]-5-oxopyrazin-2-yl]phenyl]benzamide
- A3302
- FT-0700404
- SW222244-1
- X3449
- J2.909.101C
- A11348
- F15274
- W-5786
- A860630
- N-[3-[4,5-Dihydro-4-methyl-6-[[4-(4-morpholinylcarbonyl)phenyl]amino]-5-oxo-2-pyrazinyl]-2-methylphenyl]-4-(1,1-dimethylethyl)benzamide
- Q27075885
- Btk inhibitors (autoimmune disease/inflammatory disease)
- B0084-430556
- N-[3-[4,5-dihydro-4-methyl-6-[[4-(4-morpholinylcarbonyl)phenyl]amino]-5-oxo-2-pyrazinyl]-2-methylphenyl]-4-(tert-butyl)benzamide
- Btk inhibitors (autoimmune disease/inflammatory disease), Gilead
- 4-Tert-Butyl-N-[2-Methyl-3-(4-Methyl-6-{[4-(Morpholin-4-Ylcarbonyl)phenyl]amino}-5-Oxo-4,5-Dihydropyrazin-2-Yl)phenyl]benzamide
- Btk inhibitors (autoimmune disease/inflammatory disease), Cellular Genomics
- Btk inhibitors (autoimmune disease/inflammatory disease), CGI Pharmaceuticals
- 4-tert-butyl-N-(2-methyl-3-(4-methyl-6-(4-(morpholine-4-carbonyl)anilino)-5-oxopyrazin-2-yl)phenyl)benzamide
- 4-tert-butyl-N-(2-methyl-3-(4-methyl-6-(4-(morpholine-4-carbonyl)phenylamino)-5-oxo-4,5-dihydropyrazin-2-yl)phenyl)benzamide
- 4-tert-butyl-n-(2-methyl-3-{4-methyl-6-[4-(morpholine-4-carbonyl)-phenylamino]-5-oxo-4,5-dihydro-pyrazin-2-yl}-phenyl)-benzamide
- 4-tert-Butyl-N-(2-methyl-3-{4-methyl-6-[4-(morpholine-4-carbonyl)anilino]-5-oxo-4,5-dihydropyrazin-2-yl}phenyl)benzamide
- 4-tert-butyl-N-[2-methyl-3-(4-methyl-6-{[4-(morpholine-4-carbonyl)phenyl]amino}-5-oxo-4,5-dihydropyrazin-2-yl)phenyl]benzamide
- 4-tert-butyl-N-[2-methyl-3-(4-methyl-6-{[4-(morpholine-4-carbonyl)phenyl]amino}-5-oxopyrazin-2-yl)phenyl]benzamide
- 4-tert-butyl-N-[2-methyl-3-[4-methyl-6-[4-(morpholine-4-carbonyl)anilino]-5-oxo-pyrazin-2-yl]phenyl]benzamide
- N-[2-Methyl-3-[1-methyl-5-[[4-(morpholinocarbonyl)phenyl]amino]-6-oxo-1,6-dihydropyrazine-3-yl]phenyl]-4-tert-butylbenzamide